• By James Korenchan

    USPTO SealNavigating the post-Alice patent-eligibility landscape with graphical user interface (GUI) claims can be trying, particularly when fighting to maintain desirable breadth.  As with all software-related claims, limitations must raise GUI claims (and other types of UI claims, for that matter) beyond fundamental designs and implementations, root the invention in computer technology, and provide a specific, innovative solution to a technological problem.  In the past four years, the Federal Circuit has provided some guidance for GUI claims, perhaps most notable being the recent Core Wireless decision.  In Core Wireless, the Court essentially stated that, to overcome the scrutiny of 35 U.S.C. § 101, a GUI claim should describe the specific functionality and/or layout of the GUI, and in addition, the patent's specification should describe in detail the advantages of the GUI functionality and/or layout over existing methods and designs.

    Still, despite efforts to meet these requirements, practitioners can find themselves faced with rejections citing various cases such as Internet Patents Corp. v. Active Network, Inc., Intellectual Ventures I LLC v. Erie Indemnity Co., and Intellectual Ventures I LLC v. Capital One Bank (USA), in which higher-level GUI claims were deemed patent-ineligible.  Even more dreaded is the oft-cited Electric Power Group Federal Circuit decision, used in § 101 rejections to characterize GUI claims to "collecting information, analyzing it, and displaying certain results of the collection and analysis."

    Federal Circuit decisions are certainly helpful to consider in prosecuting GUI claims.  The goal of this post, however, is to highlight a small handful of Patent Trial and Appeal Board (PTAB) appeal decisions from the past three months as examples of how the Board has been addressing GUI claims of late.

    In May, for instance, the PTAB affirmed the patent-ineligibility of claims directed to a GUI display for use in locating buried or otherwise inaccessible "utility lines," such as pipes and other conduits, cables, transmitters, etc. by using sensors to detect electromagnetic signal emissions from buried or hidden objects.  The patent application (U.S. Patent App. No. 13/189,844) noted that advances in inexpensive processing power and complex software systems have made it possible to improve locator performance using a GUI to present data obtained from such sensors, such as a direction of current flow.  The application went on to note that there still exist unresolved problems in the field, and the claimed GUI was one of a handful of proposed solutions.  For example, the application described the claimed GUI as incorporating "intuitive" displays that more accurately display representations of signal quality to a user so that no confusion exists as to whether sensor data indicates that a utility line has been found.  However, claim 1, shown as follows, did not appear to sufficiently convey any alleged improvement to GUI display or to the determination of the displayed information.

    1.  A graphical user interface (GUI) display method in a portable locator system for locating a utility line coupled to a phase-encoded modulated electromagnetic (EM) reference signal, the method comprising the steps of:
        measuring, at the locator system, a three dimensional magnetic field generated at least in part based on the phase-encoded modulated EM reference signal;
        determining a current flow based on the measured magnetic field;
        determining a direction of the current flow based on the phase-encoding of the modulated EM reference signal; and
        displaying, on the GUI, a representation of the direction of the current flow.

    In rejecting this claim, the Examiner deemed the claim to be directed to an abstract idea of an algorithm for measuring and determining a direction of current flow, and cited both Diamond v. Diehr and Electric Power Group.  And with regard to Electric Power Group, the Board equated the "measuring" step to data gathering, equated the middle two steps as processing gathered data, and deemed the display of current flow direction to be an insufficient post-solution activity.  The Appellants' attempt at distinguishing over Electric Power Group stated that the claims "have nothing to do with" measuring current direction and instead provide an improved process for using current direction to help find information about buried utilities and for processing signals emitted from the utility.  The Appellants further asserted that the claims use this alleged improved process to in turn improve the technology of providing a visual representation of detected buried utilities.  Still, the Examiner and the Board did not waver on step one of Alice.  In addition, the Board found no additional features sufficient for elevating the claim to the realm of patent-eligibility.  (The Board also sustained a § 102 rejection of claim 1.)

    In June, the PTAB also affirmed the patent-ineligibility of claims directed to a GUI that allows medical personnel to document medical procedures and automatically generate billing information for the procedures.  The patent application (U.S. Patent App. No. 13/103,129) aimed to reduce time spent summarizing procedure details and generating bills, as well as to reduce errors found in procedure summaries and resulting bills, such as errors that occur when doctors forget or insufficiently document acts performed during procedures.  Claim 1 is provided as a representative example.

    1.  A non-transitory computer-readable medium having stored thereon sequences of instructions which, when executed by at least one processor, cause the at least one processor to:
        output a graphical user interface (GUI), the GUI including a visual representation of at least a portion of a human body and a text input area;
        receive input from a user via the GUI, the input selecting portions of the visual representation and identifying a sequence of medical procedures that were performed on a patient with respect to the selected portions;
        highlight the selected portions on the visual representation, the highlighted portions providing a graphical representation of the sequence of medical procedures that were performed on the patient;
        automatically generate billing codes corresponding to the medical procedures that were performed based on the input received via the GUI;
        automatically generate text, based on input received via the GUI, identifying at least some of the medical procedures that were performed;
        display the billing codes and the generated text on the GUI;
        provide, via the GUI, a pop-up or dialog window in response to input corresponding to at least some of the medical procedures that were performed;
        receive, from the user, information via the pop-up or dialog window; and
        display at least some of the information provided via the pop-up or dialog window in the text input area of the GUI,
        wherein the sequence of medical procedures corresponds to surgery performed on the patient and the visual representation displays a portion of a vascular system of the human body, and
        wherein when highlighting the selected portions, the instructions cause the at least one processor to highlight a path in the displayed portion of the vascular system corresponding to portions of the vascular system in which the surgery was performed.

    In rejecting claim 1, the Examiner stated that the claimed invention "merely encompasses the abstract ideas of comparing new and stored information and using rules to identify options; and/or using categories to organize, store and transmit information."  The Appellants then argued that the claims were mischaracterized and that not all of the claim features were considered.  In particular, that Appellants stated in their reply brief that:

    Claim 1, however, recites a much more detailed set of features that provide a comprehensive solution to documenting medical procedures in a visual manner (e.g., by highlighting selected portions of the visual representation), while ensuring that needed information and text are provided (e.g., via input from the GUI and pop-up or dialog window), that text and billing codes are automatically generated for billing purposes, and that a highlighted path is displayed that corresponds to the portions of the vascular system in which the surgery was performed.  Such features provide medical personnel with a comprehensive visual representation, along with text and billing codes.

    But the Board concluded that the Examiner's characterization was proper because "different levels of abstraction" can be applied in an Alice step-one analysis.  Unfortunately, the Appellants' arguments with regard to step two were relatively lacking, and the Board concluded that the Appellants did not identify or provide supporting explanation for additional elements that amount to significantly more than an abstract idea.  Instead, the Appellants restated the above-noted improvements to the field of documenting and billing medical procedures, and then proceeded to unsuccessfully argue that the claimed features are not well understood, routine, and conventional because there was no prior art rejection of claim 1.  The Board very quickly dismissed these arguments.  Had the Appellants cited to the specification in step two and tied described advantages to particular claim limitations, they might have set themselves off on a better foot with the Board (and possibly with the Examiner), though it is difficult to say whether this would have been persuasive.

    As an interesting point of comparison to the medical documenting/billing claim in the previous case, the Board also recently reversed a § 101 rejection of claims in the medical field (albeit arguably claims with more-detailed functionality).  In particular, in U.S. Patent App. No. 14/271,719, the claims relate to a "GUI wizard" used to help human personnel audit and score medical documents that have undergone a process in which clinical contents of the documents, such as medical findings, diagnoses, and procedures, are "coded" (i.e., mapped to standardized alphanumeric nomenclature codes).  The application describes that coding has traditionally been done manually, and that the auditing of coding results is heavily dependent on human skills and prone to human error.  The claimed GUI method thus aims to make the auditing and scoring process less complex and reduce errors.  Representative claim 37 is provided as follows:

    37.  A method of evaluating coded medical documents performed by a computer, the method comprising:
        [1] providing, by a computer, a graphical user interface (GUI) wizard;
        [2] receiving, by the computer via the GUI wizard, audit parameters for selecting a document universe and for calculating a sample size;
        [3] calculating, by the computer, a sample size using the received audit parameters;
        [4] selecting, by the computer, a document universe based on the received audit parameters;
        [5] providing, by the computer via the GUI wizard, a plurality of medical documents coded by a coder and selected using the selected document universe and the calculated sample size;
        [6] receiving, by the computer via the GUI wizard, a plurality of corrections by an auditor to the plurality of medical documents;
        [7] recording, by the computer, the plurality of corrections to the coded medical documents to form a plurality of audited medical documents;
        [8] determining, by the computer, a document score for each of the plurality of audited medical documents, each document score based on one or more document corrections provided by the auditor and weighted factors, wherein the weighted factors comprise predefined weights assigned to diagnosis codes and finding codes of each of the plurality of audited medical documents;
        [9] determining, by the computer, a sample score for the plurality of audited medical documents based on the determined document scores;
        [10] determining, by the computer, the acceptability of the sample score by periodically performing an empirical test to compare the sample score to system control limits; and
        [11] displaying, by the computer via the GUI, an X-bar chart analysis comprising the sample score, an upper control limit, a lower control limit, and a previously determined sample score of audited medical documents coded by the coder.

    In rejecting this claim, the Examiner argued that the claims were directed to an abstract idea of "determining the acceptability of a determined sample score that is based on determined document scores of audited medical documents."  In response, the Appellants contended that the claims recite specific UI elements (e.g., a GUI wizard and an X-bar chart analysis) that define a specific user experience.  Analogizing to the claims in Core Wireless, the Board sided with the Appellants, finding the claim to be directed to an improved GUI wizard and specifically identifying steps [2], [5], [6], and [11] of the claim as sufficiently inventive features.  Notably, the Board emphasized how these and other claimed steps are described in detail in the specification along with details as to how the steps, as well as the GUI layout, help a user audit coded medical documents.  The Board stopped its analysis after step one, concluded that the claims are patent eligible, and reversed the Examiner's rejection.

    Ex parte Ahn (PTAB 2018)
    Panel: Administrative Patent Judges Astorino, Meyers, and Silverman
    Decision on Appeal by Administrative Patent Judge Silverman

    Ex parte Olsson (PTAB 2018)
    Panel: Administrative Patent Judges Colaianni, Housel, and McManus
    Decision on Appeal by Administrative Patent Judge Housel

    Ex parte Heinze (PTAB 2018)
    Panel: Administrative Patent Judges Lorin, Medlock, and Bayat
    Decision on Appeal by Administrative Patent Judge Lorin

  • By Kevin E. Noonan

    FDAEarlier this month, the U.S. Food and Drug Administration announced a new initiative, the Biosimilars Action Plan: Balancing Innovation and Competition in furtherance of its efforts "to ensure that this balance between innovation and competition exists across the spectrum of pharmaceutical products."  The hoped-for outcome of the BAP:  that "[a]fter patents or other exclusivities expire on these novel products, prices can fall dramatically once follow-on products are available, potentially lowering costs for patients and payors and expanding access to these innovations."

    The Introduction states that:

    The agency is taking steps to more efficiently manage our review and licensure pathways to facilitate biosimilar competition.  We are modernizing our policies that govern the development of biosimilar to make it more efficient.  We are also educating clinicians, payors and patients about biosimilar products and the rigorous evaluation they must go through.  And, we are modernizing regulatory policies to accommodate new scientific tools that can better enable comparison between biosimilars and reference products that may reduce the need for clinical studies.

    Some of the bureaucratic measures the agency intends to implement in furtherance of these efforts include:

    1.  Introducing new FDA tools to improve efficiency of FDA review (e.g., templates "tailored to marketing applications for biosimilar and interchangeable products")
    2.  Creating information resources and development tools for biosimilar applicants (in silico models and simulations for correlating PK/PD responses to clinical outcomes)
    3.  Enhancing the Purple Book
    4.  Looking into data sharing agreements with foreign regulators
    5.  Establishing a new Office of Therapeutic Biologics and Biosimilars to improve coordination under the BsURA program
    6.  Providing critical education to health care professionals
    7.  Finalizing Guidance on labeling
    8.  Providing finalized Guidance on interchangeable biosimilars
    9.  Improving analytical approaches for structure/function for demonstrating biosimilarity including statistical methods
    10.  Implementing standards for manufacturing quality control
    11.  Improving public dialog with hearings and requests for public input on FDA actions to evaluate and promote biosimilars

    Why now?  The FDA contends that "[t]his is a crucial time in the emergence of the marketplace of biosimilar and interchangeable products."  The agency expects continued expansion in the number of approved biosimilar and interchangeable products in the coming years.  The announcement of this new initiative recognizes "barriers to marketing a biosimilar or interchangeable product that are outside of the FDA's purview," but assert that it is part of the agency's mandate to "advance[e] policies to facilitate the efficient development and approval of these products."  Hence, the enunciation of the BAP.

    There are four "key elements" of the BAP:

    1.  Improving the efficiency of the biosimilar and interchangeable product development and approval process

    How?

    • Providing application review templates, formatted for 351(k) BLA requirements
    • Transitioning to a Therapeutic Biologics and Biosimilars Staff (TBBS) from the Office of New Drugs under Center for Drug Evaluation and Research (CDER) to the Office of Therapeutic Biologics and Biosimilars (OTBB), intended to "improve coordination and support" of activities under the Biosimilar User Fee Act (BsUFA), increase agency response times, and improve efficiencies in policy development and response to applicants
    • Improve coordination with CDER
    • Develop information resources for biosimilar applicants, such as an "index of critical quality attributes" for comparing reference products to biosimilars, and comparison metrics that will reduce the size of clinical studies

    2.  Maximizing scientific and regulatory clarity for the biosimilar product development community

    How?

    The FDA has issued six final (see "Nonproprietary Naming of Biological Products"; "Considerations in Demonstrating Interchangeability with a Reference Product"; "Clinical Pharmacology Data to Support a Demonstration of Biosimilarity to a Reference Product"; "Scientific Considerations in Demonstrating Biosimilarity to a Reference Product"; "Quality Considerations in Demonstrating Biosimilarity of a Therapeutic Protein Product to a Reference Product"; and "Biosimilars: Questions and Answers Regarding Implementation of the Biologics Price Competition and Innovation Act of 2009") and four draft (see "Scientific Considerations in Demonstrating Biosimilarity to a Reference Product"; "Quality Considerations in Demonstrating Biosimilarity to a Reference Protein Product"; "Biosimilars: Questions and Answers Regarding Implementation of the Biologics Price Competition and Innovation Act of 2009," as discussed in "FDA Publishes Draft Guidelines for Biosimilar Product Development" and "More on FDA Draft Guidelines for "Follow-on" Biologic Drug Approval Pathway") Guidance documents relating to biosimilars.  The FDA expects additional Guidances to be forthcoming that will involve public hearings, prioritizing the following issues:

    • Final or Revised Draft Guidance: Reference Product Exclusivity for Biological Products Filed Under Section 351(a) of the PHS Act
    Final or Revised Draft Guidance: Implementation of the "Deemed to be a License" Provision of the Biologics Price Competition and Innovation Act of 2009
    Final or Revised Draft Guidance: Considerations in Demonstrating Interchangeability with a Reference Product
    Final or Revised Draft Guidance: Statistical Approaches to Evaluate Analytical Similarity
    Draft Guidance: Processes and further considerations related to post-approval manufacturing changes for biosimilar biological products

    The agency is also developing guidance for biosimilar applicants who will seek approval for fewer than all conditions for which the reference product is licensed, and developing a formal rule for interpreting the definition of "biological product" under the BPCIA, to provide additional "clarity."  FDA is evaluating regulations regarding aBLA submission, and working on an enhanced Purple Book (which will contain "information about newly approved or withdrawn BLAs and about reference product exclusivity determination").

    Finally, under this part of the BAP, the agency will be "[s]trengthening its partnerships with regulatory authorities in Europe, Japan and Canada" by "harmonizing requirements for their development as well as sharing regulatory experience across national boundaries," including data sharing agreements to increase the use of non-U.S.-licensed comparator products to support biosimilar application.

    3.  Developing effective communications to improve understanding of biosimilars among patients, clinicians, and payors

    How?

    This portion of the Plan is aimed at increased educational efforts according to the Biosimilar Education and Outreach Campaign released in October 2017; continuing efforts including videos, webinars, information on the webpage, and providing educational materials for patients, pharmacists, and other stakeholders.

    4.  Supporting market competition by reducing gaming of FDA requirements or other attempts to unfairly delay competition

    How?

    In many ways the most provocative part of the Plan, the announcement states that:

    The FDA will clarify our position on issues affecting reference product exclusivity to better effectuate balance between innovation and competition.  We will also take action, whenever necessary, to reduce gaming of current FDA requirements, and coordinate with the Federal Trade Commission to address anti-competitive behavior.  Additionally, we will work with legislators, as needed to close any loopholes that may effectively delay biosimilar competition beyond the exclusivity periods envisioned by Congress.

    The FDA intends to take steps for biosimilars analogous to the Drug Competition Action Plan (DCAP) the agency has implemented for generic drugs, where it was "a priority to address practices that delay or block competition from entering the market."  For generic drugs, these efforts were aimed at preventing branded drug makers from activities such as "refusal to sell the samples necessary for developing generic drugs [a practice we've seen with products under limited distribution, whether the drug maker limits distribution voluntarily or does so in connection with a Risk Evaluation and Mitigation Strategy (REMS) program]."  Insofar as such practices are being used by reference product sponsors (and the announcement does not provide any examples of such behavior, the agency states that "[w]e will apply the same principles used in DCAP to our BAP to address circumstances in which drug makers refuse to sell samples, or use any other anticompetitive strategies, to delay the entry of biosimilar or interchangeable development and competition."

    In conclusion, the FDA says it expects development of biosimilar and interchangeable drugs to "continue to evolve" and thus implementation of the BAP to be "dynamic."  And:

    The FDA is committed to transparent, science-based regulation of biosimilar and interchangeable products that maintains the dynamic balance between innovation and timely access, as Congress intended.  Appropriate market exclusivities allow innovators to recoup their investments, and compensate them for the time, risk and uncertainty that make the cost of capital to undertake these endeavors high.  These rewards provide incentives for research and development of new treatment options, as well as help advance medical innovation and improve outcomes.

    While a good deal of this announcement is conventional bureaucratic promotion, there are a few nuggets that suggest that the FDA under this Administration may be more confrontational and aggressive towards perceived "bad behavior" by certain of its shareholders.  It is certainly the case that the price of drugs, particularly biologic drugs, is high and poses a significant cost burden on the health care system as a whole (both public and private).  The BAP appropriately addresses these concerns and recognizes that they must be addressed.  But it is also good to try to understand the economic realities that have created the situation (without excessive and unproductive finger-pointing).  It is a truism that everything has increased in price (and many things even adjusted for inflation); after all, it isn't just the elderly that are confronted with prices that seem ridiculously excessive.  But for drugs it also must be recognized, by policy makers as well as the public, that the low-hanging fruit of small molecule drugs and those with (relatively) simple etiologies have been discovered in the first flowering of the modern pharmaceutical intervention in human disease (see, e.g., Epstein, 2006, Overdose: How Excessive Government Regulation Stifles Pharmaceutical Innovation; and Rosen, 2017, Miracle Cure: The Creation of Antibiotics and the Birth of Modern Medicine).  And federal regulation, particularly by the FDA, is more extensive and costly than it was prior to the thalidomide tragedy in 1962.  While it is convenient and politically expedient to castigate the pharmaceutical industry for high prices, it is foolhardy not to recognize these and other factors in producing the current price situation.

    The context of the comments in the FDA's BAP also comprises statements by Commissioner Gottleib regarding the possibility of changing U.S. drug importation regulations (but with disclaimers regarding exclusivities and prompted by "supply chain disruptions" to soften the political effects of implied threat) to permit "temporarily" importation of drugs from foreign sources.  The FDA has also created a task force to address drug shortages, either due to supply chain difficulties or source monopolization of unpatented drugs without remaining regulatory exclusivity due to sole sourcing.

    But there is another aspect that is typically overlooked.  For many biologic drugs, the diseases they address are ones that a generation ago resulted in significant morbidity and mortality; indeed, some diseases were invariably fatal (many cancers, HIV) or severely debilitating (kidney disease, hepatitis).  Some of these were diseases of the elderly, and the wisdom of expending vast sums to extend few lives for short times is a topic for another day.  But for the overwhelming number of cases where individuals in the prime of life are cured or their diseases managed, these drugs provide significant advantages, both for the afflicted individuals and society as a whole.  In the most hard-hearted, dollars-and-cents analysis, what pundits who bemoan high drug costs appear to forget is that these individuals are returned to the workforce as productive participants, who hold down jobs and pay taxes and participate in the U.S. consumer economy.  Society, whether in the form of local or nationwide businesses or federal, state, and local tax collectors, reaps the benefit of those who have returned to the workforce due to the effects of biologic drugs that did not exist twenty, ten, five, or even one year ago.

    And that doesn't take into account the human benefits, which now routinely permit individuals (and their spouses, sons, daughters and grandchildren) to enjoy the benefits of longer life and participation in weddings, births, and other lifetime milestones.  Undue focus on the goal — obtaining biologic drugs at reduced prices — raises a risk of not having these drugs, or their benefits, because private investment is frustrated and the government is a generally a poor source of innovation.  It would be well for policymakers, particularly at FDA, to keep such considerations in mind to temper their fiscal zeal.

  • Catalog Distributed at Conference (Not "Open to the Public") Is Publicly Accessible

    By Joseph Herndon

    Federal Circuit SealGoPro, Inc. appealed from final written decisions of the Patent Trial and Appeal Board in two inter partes review (IPR) proceedings.  In the proceedings, the Board found that the petitioner, GoPro, did not demonstrate that the challenged claims were unpatentable as obvious, and based this decision on its finding that a certain GoPro catalog was not a prior art printed publication.  The sole issue on appeal is whether the GoPro catalog is prior art.

    Contour IP Holding LLC owns U.S. Patent Nos. 8,890,954 and 8,896,694.  The patents share a common specification that generally relates to and describes action sport video cameras or camcorders that are configured for remote image acquisition control and viewing.  According to the patents, the claimed device uses global positioning system (GPS) technology to track its location during recording and a wireless connection protocol, such as Bluetooth, to provide control signals or stream data to the wearable video camera and to access image content stored on or streaming from the wearable video camera.

    The patents further describe that when recording video or taking photographs in a sports application, a digital video camera is often mounted in a location that does not permit the user to easily see the camera.  The digital camera includes wireless communication capability to allow another device, such as a smartphone or tablet, to control camera settings in real time, access video stored on the camera, and act as a "viewfinder" to preview what the camera sees.

    Both the '954 and '694 patents claim priority to a provisional application filed on September 13, 2010.  Thus, the one-year critical date is September 13, 2009.

    GoPro petitioned for inter partes review of the '954 and '694 patents and challenged the patentability of the claims on obviousness grounds, relying on a 2009 GoPro sales catalog as prior art in each petition.  The GoPro Catalog discloses a digital camera linked to a wireless viewfinder/controller that allows for a user to preview before recording.

    The Board instituted both IPRs, and in its decisions to institute, the Board found that GoPro made a threshold showing that the GoPro Catalog is prior art.  After the hearing, however, the Board found that the GoPro Catalog did not qualify as a prior art printed publication under 35 U.S.C. § 102(b), and because all the instituted grounds were based on the GoPro Catalog, the Board found that GoPro had not demonstrated that the challenged claims of the '954 and '694 patents were unpatentable under 35 U.S.C. § 103.  GoPro appealed from these final written decisions to the Federal Circuit.

    On appeal, neither the claim terms nor the claimed inventions are at issue in this appeal.  The only issue is whether the GoPro Catalog is prior art.  The '954 and '694 patents each have an effective filing date before the effective date of the Leahy-Smith America Invents Act ("AIA").  Thus, the pre-AIA version of 35 U.S.C. § 102 was applied.

    Section 102(b) provides that a person shall be entitled to a patent unless the invention was described in a printed publication more than one year prior to the date of application for patent in the United States.  The printed publication rule is based on the principle that once an invention is in the public domain, it can no longer be patented by anyone.  Even relatively obscure documents qualify as prior art so long as the relevant public has a means of accessing them.

    The most commonly referenced example is that even a single cataloged thesis in a university library was found to be sufficiently accessible to those interested in the art exercising reasonable diligence.  Accessibility goes to the issue of whether interested members of the relevant public could obtain the information if they wanted to and if accessibility is proved, there is no requirement to show that particular members of the public actually received the information.  Accordingly, a reference will be considered publicly accessible if it was disseminated or otherwise made available to the extent that persons interested and ordinarily skilled in the subject matter or art exercising reasonable diligence, can locate it.

    Critical to its decision, the Board credited a declaration from GoPro employee, Damon Jones, relating to the distribution of the GoPro Catalog.  Mr. Jones worked at GoPro from 2008 to 2016 and participated in various trade organizations relevant to GoPro's business.  This included Tucker Rocky Distributing ("Tucker Rocky"), a trade organization focused on action sports.  In his declaration, Mr. Jones testified that Tucker Rocky holds an annual dealer trade show, which he attended in Fort Worth, Texas, from July 23 through July 27, 2009, on GoPro's behalf.  Mr. Jones also testified that at the 2009 show, there were approximately 150 vendors and more than 1,000 attendees, including actual and potential dealers, retailers, and customers of portable POV video cameras.  Mr. Jones stated that he manned the GoPro booth at the show, where the GoPro Catalog was displayed, and that he personally distributed the GoPro Catalog to attendees.  Attached to Mr. Jones's declaration, GoPro provided the catalog, a vendor list and map of the Tucker Rocky 2009 show, and email records supporting Mr. Jones's statements.  The declaration from Mr. Jones also included testimony that GoPro continued to make the GoPro Catalog available to GoPro's actual and potential customers, dealers, and retailers through its website, direct mail, and other means of distribution.

    In its Patent Owner Responses, Contour argued that GoPro had not demonstrated that the GoPro Catalog was a prior art printed publication.  To support its argument, Contour submitted two pieces of evidence—a screenshot from Tucker Rocky's website from 2009 and a Facebook webpage for the 2013 Tucker Rocky Dealer Show.  The 2009 website screenshot explained that Tucker Rocky is a wholesale distributor that does not sell to the public.  The 2013 Facebook page stated that the 2013 Tucker Rocky Dealer Show was open to dealers but not the public.  In its final written decisions, the Board concluded that GoPro had not met its burden to show that the GoPro Catalog was disseminated or otherwise made available to the extent that persons interested and ordinarily skilled in the subject matter or art and exercising reasonable diligence could have located it.

    On Appeal, the parties did not dispute any of the facts or evidence presented by GoPro regarding the distribution of its catalog.  In addition, there is no dispute that the Tucker Rocky Dealer Show occurred before the critical date of the '954 and '694 patents.  The only issue on appeal is whether the GoPro Catalog was sufficiently accessible as contemplated under § 102(b).

    The Federal Circuit reversed the Board's decision, and agreed with GoPro in that Mr. Jones's declarations and corroborating evidence were sufficient to meet its burden of establishing that the GoPro Catalog was publicly accessible.  The Federal Circuit noted that the case law regarding accessibility is not as narrow as the Board interpreted it.  The Board focused on only one of several factors that are relevant to determining public accessibility in the context of materials distributed at conferences or meetings—i.e., that the conference was open to the public.

    However, the nature of the conference or meeting must be considered.  The Federal Circuit found that if one desires to examine certain new products on the market, attending a trade show involving identical or similar products is a good option.  Mr. Jones testified that Tucker Rocky holds an annual trade show that draws thousands of attendees.  In 2009, GoPro participated in the Tucker Rocky Dealer Show as a vendor and had a demonstration booth at the show.  Mr. Jones testified that there were over 150 vendors, 1,000 attendees, and that GoPro displayed and distributed hundreds of copies of the GoPro Catalog to attendees at the show without restriction.

    The Patent Owner did not cross-examine Mr. Jones, and does not point to any reason to doubt the veracity of his testimony.

    Although the trade show was only open to dealers, there is no evidence or indication that any of the material disseminated or the products at the show excluded POV action cameras, or information related to such cameras.  Contrary to the Board's conclusion, the attendees attracted to the show were likely more sophisticated and involved in the extreme action vehicle space than an average consumer.  Thus, it is more likely than not that persons ordinarily skilled and interested in POV action cameras were in attendance or at least knew about the trade show and expected to find action sports cameras at the show.

    The Board concluded that the GoPro Catalog was not a printed publication because the Tucker Rocky Dealer Show was not open to the general public and GoPro failed to provide evidence that someone ordinarily skilled in the art actually attended the dealer show.  But the Federal Circuit found that the standard for public accessibility is one of reasonable diligence to locate the information by interested members of the relevant public.  A dealer show focused on extreme sports vehicles is an obvious forum for POV action sports cameras.  And although the general public at large may not have been aware of the trade show, dealers of POV cameras would encompass the relevant audience such that a person ordinarily skilled and interested in POV action cameras, exercising reasonable diligence, should have been aware of the show.

    Additionally, the GoPro Catalog was disseminated with no restrictions and was intended to reach the general public.  Because the Board refused to accept the GoPro Catalog as a printed publication, it did not consider the merits of GoPro's obviousness claims.  The Federal Circuit thus remanded the case for consideration of the catalog as prior art.

    GoPro, Inc. v. Contour IP Holding LLC (Fed. Cir. 2018)
    Panel:  Circuit Judges Reyna, Wallach, and Hughes
    Opinion by Circuit Judge Reyna

  • En Banc Federal Circuit Finds § 145 Appellants Generally Will Not Be Liable for Patent Office's Attorneys' Fee

    By Kevin E. Noonan & Josh Rich

    Federal Circuit SealThe Federal Circuit handed down its en banc decision on Friday regarding the question of whether under 35 U.S.C. § 145 an applicant must pay attorneys' fees as part of the "expenses" the statute mandates, in NantKwest, Inc. v. Iancu (Fed. Cir. 2018) (en banc).  Generally, under the "American Rule," parties in U.S. litigation are responsible for their own fees regardless of the outcome of the case.  In NantKwest, Inc. v. Iancu, the U.S. Patent Office sought to turn that rule on its head for appeal from adverse patent decisions, wherein the Patent Office would recover its attorneys' fees — along with all other expenses — regardless of whether the applicant won or lost the case.  The District Court rejected the Patent Office's argument, and a divided panel of the Federal Circuit reversed the District Court's decision and ordered payment of the Patent Office's fees.  The Federal Circuit chose to review the panel's decision sua sponte.  The en banc Federal Circuit affirmed the District Court's decision, over a spirited dissent, holding that the Office was not entitled to its attorneys' fees in appeals under § 145.

    There are two ways to appeal an adverse Patent Trial and Appeal Board decision arising out of patent prosecution (§ 145 appeals are not available for reexamination, post-grant and inter partes review, or derivation proceedings).  First, under 35 U.S.C. § 141(a), a dissatisfied applicant can pursue an appeal to the Federal Circuit as a routine appeal of an agency decision under the Administrative Procedure Act.  In such an appeal, the review is confined to the record before the Patent Office.  Second, under 35 U.S.C. § 145, the applicant can bring a civil action in the U.S. District Court for the Eastern District of Virginia.  In such an action, the parties can conduct full discovery and introduce new evidence, including oral evidence, that was not presented to the Patent Office in prosecution.  The § 145 action is resolved by the same methods generally used in other district court cases, including motion practice and trial on the merits.

    One downside of appealing under § 145 has always been financial:  the statute provides that "[a]ll the expenses of the proceedings shall be paid by the applicant."  Ever since the predecessor to the current statute was enacted in 1839, the Patent Office had required a § 145 appellant to pay expenses including travel expenses, expert fees, and document reproduction costs, but not attorneys' fees.  That changed with the NantKwest case, where the Patent Office — for the first time in over 170 years — demanded that NantKwest pay the Patent Office's attorneys' fees incurred in the § 145 action, win or lose.

    The majority and dissent reached opposite conclusions based on two major distinctions.  First, the majority placed the emphasis on the statutory language "expenses," not "all"; the dissent focused on "all" rather than "expenses."  The majority also considered the language somewhat vague, not "specific and explicit," whereas the dissent considered it so clear as to not need further consideration as to clarity.  Surprisingly, however, neither the majority nor the dissent placed much emphasis on the Patent Office's 170 years of conduct under the statute, which would seem to be the clearest indication of what it believed the statute to mean at the time of enactment and many years thereafter.

    The en banc majority started its attorneys' fees analysis with the American Rule as a "bedrock principle" of American jurisprudence:  that each party pays its own attorneys' fees, win or lose.  The American Rule is rooted in fair access to the legal system for the poor, as well as the difficulty of litigating the reasonableness of fees.  That is, the American Rule — unlike the presumption in England — chooses to value allowing less wealthy litigants to contest a case over demanding that a prevailing party avoid any loss whatsoever from litigation.

    The American Rule does not apply in all cases, however; Congress has, from time to time, chosen to establish a presumption in certain cases that a prevailing litigant will recover attorneys' fees.  No magic words are required for fee-shifting, but for a law to do so, according to the Supreme Court, Congress's intent must be "specific and explicit"; see, Runyon v. McCrary, 427 U.S. 160, 185 (1976).

    The majority first considered whether the presumption of the American Rule applied under § 145.  The Patent Office argued that it should not, because it relates only to cases in which fees are shifted from a losing party to a prevailing party.  The Patent Office relied heavily on a Fourth Circuit case, Shammas v. Focarino, 784 F.3d 219 (4th Cir. 2015), in which language from the Lanham Act nearly identical to § 145 was held not to require consideration of the American Rule in compelling an appellant's payment of the Patent and Trademark Office's attorneys' fees in trademark cases.  The majority chose to reject the Shammas holding, finding that it "cannot be squared with the Supreme Court's line of non-prevailing party precedent applying the American Rule."  The Patent Office also relied on Sebelius v. Cloer, 569 U.S. 369 (2013), which interpreted a statute that allows prevailing "Vaccine Court" petitioners to recover reasonable attorneys' fees, but also permits a discretionary award of fees for unsuccessful petitions "brought in good faith [with] a reasonable basis for the claim."  The majority did not dispute or reject the Supreme Court's Sebelius holding, but found that the underlying statute was a straightforward instance of a specific and explicit intent by Congress to overcome the presumptive American Rule.  As a result, the majority found no reason to avoid the presumption of the American Rule in determining whether § 145 required an applicant to pay the Patent Office's attorneys' fees.

    The majority thus started with the presumption of the American Rule and considered whether § 145's requirement that the applicant pay "all of the expenses of the proceedings" showed a specific and explicit intent to overcome the American Rule.  In doing so, it viewed the key question as whether attorneys' fees would be considered "expenses" in the context of § 145, which meant an investigation of the meaning of the term in 1839.  While one dictionary definition would support a meaning that would include attorneys' fees, the majority found that most contemporaneous dictionary definitions would not.  Similarly, other statutes' use of "expenses" generally did not include attorneys' fees.  In some cases, the statutes identified expenses and attorneys' fees as different categories, some others explicitly included attorneys' fees in expenses.  And where the Patent Act discusses fee awards (specifically, § 285), it does so explicitly, with language quite different from the more general term "expenses" used in § 145.  Furthermore, judicial decisions (both from the mid-1800s and more recently) in relation to expenses and attorneys' fees have viewed the two as separate categories.  Finally, the majority considered that the Patent Office's interpretation would require a prevailing appellant to pay the losing Patent Office's attorneys' fees.  Such an anomalous departure from the presumption of the American Rule would require extraordinary clarity in the statute; the majority did not find it.  Thus, the majority did not find the specific and explicit intent to overcome the American Rule and refused to award the Patent Office its attorneys' fees as part of "all of the expenses of the proceedings" in a § 145 case.

    Having reached a conclusion based on its analysis of the statutory language, judicial decisions, and contemporaneous interpretation, the majority dealt with additional policy and legal arguments raised by the Patent Office and dissent.  It discussed the Patent Office's citations to Supreme Court cases, finding the language did not support the Patent Office's arguments when read in context.  It then dealt with the dissent's citation of the legislative history of the 1870 amendment to § 145's predecessor.  First, honoring the legacy of Justice Scalia, the majority questioned whether legislative history should even be considered.  But even so, it found that the legislative history was opaque in changing the statutory language from "costs" capped at $25 to uncapped "expenses."  Certainly, the majority agreed, that was intended to broaden the recoverable amounts, but it provided no guidance as to whether attorneys' fees was intended to be one of the recoverable categories.  The majority also rejected the dissent's reliance on the Patent Office's 1836 budgetary provisions (which included salaries of employees as one of the "expenses of the Patent Office") as being such a different context as to be uninformative.  Finally, it rejected the dissent's suggestion that § 145 actions would be scourge on the patent system as a whole if the Patent Office were required to pay its own attorneys' fees.  There are only a handful of § 145 actions per year — if that many — and the Patent Office's attorneys' fees can be spread over hundreds of thousands of applications.  As the majority calculated it, the attorneys' fees from § 145 actions adds up to less than $2 per application, scarcely a disabling imposition.

    Thus, having rejected the Patent Office's arguments, the majority found that the general American Rule should apply and parties to § 145 actions should pay their own attorneys' fees.  It demanded specific and explicit evidence of a Congressional intent to deviate from the American Rule and found none, either in the statutory language or other evidence.  While the Fourth Circuit came to the opposite conclusion in the Shammas case (in the trademark context), the Federal Circuit concluded that Shammas's interpretation of the governing law (both statutory language and case law) was wrong.  There was insufficient evidence to overcome the American Rule and a dissatisfied applicant's payment of "all of the expenses of the proceedings" in a § 145 action does not require it to pay the Patent Office's attorneys' fees.

    The dissent

    Chief Judge Prost's dissent (joined by Judges Dyk, Reyna, and Hughes) makes the more straightforward (if not better) argument.  Its straightforwardness comes from the plain language of the statute, that an applicant who avails herself of the provisions of § 145 must pay "all expenses of the proceedings."  Expenses according to the dissent would include attorneys' fees (despite the long history to the contrary), and use of the word "all" further supports this construction of the statute.  The Fourth Circuit employed a similar construction to 15 U.S.C. § 1071(b)(3) (having language regarding expenses "almost identical" to the language of § 145) in Shammas v. Focarino, 784 F.3d 219 (4th Cir. 2015), and another reason put forth in the dissent was the perceived (unnecessary) circuit split that the majority's decision raises.

    The dissenting opinion notes that a disappointed applicant has two options for appeal:  direct appeal to the Federal Circuit and recourse to the district court at issue in this appeal.  "Litigation in district court is expensive and time-consuming, much more so than direct appeals to this court limited to the administrative record," the opinion reminds us (although in view of the difference between the resources of the Federal government and most applicants this seems not particularly relevant to the statutory construction issue before the Court).  Citing Hyatt v. Kappos, 625 F.3d 1320, 1337 (Fed. Cir. 2010) (en banc), aff'd and remanded, 566 U.S. 431 (2012), the opinion emphasizes that an applicant must pay "all expenses of the proceedings" and this responsibility attaches "regardless of the outcome," i.e., whether the district court rules for or against the applicant.  The dissent then points out PTO outlays in this case, for expert witnesses (which payments are not at issue) and agency attorneys (which are) and that the Office did not employ outside counsel.  The significance (insofar as there is any) of this arrangement was that the "expenses" for using these lawyers stemmed from "the time they devoted to this case was not available for other work," citing Wis. v. Hotline Indus., Inc., 236 F.3d 363, 365 (7th Cir. 2000), as precedent for these considerations.  As evidence of the PTO's frugality and absence of overreach, the dissent noted that "the PTO is not seeking reimbursement for its lawyers' time at market rate" but rather for "personnel expenses it actually incurred in these proceedings."

    Regarding how the term "expenses" should be construed, the dissent looks at the meaning of the term when the Patent Act of 1836 was enacted (and the district court option first became available to applicants), specifically:

    [T]he applicant shall pay into the Treasury of the United States, or into the Patent Office, or into any of the deposit banks to the credit of the Treasury . . . the sum of thirty dollars . . . .  And the moneys received into the Treasury under this act shall constitute a fund for the payment of the salaries of the officers and clerks herein provided for, and all other expenses of the Patent Office, and to be called the patent fund.  Patent Act of 1836, ch. 357, § 9, 5 Stat. 117, 121 (emphasis added).

    While acknowledging that "expenses of the Patent Office" and "expenses of the proceedings" is not exactly the same language, the dissent relied upon this language to establish that Congress (perhaps) in 1836 'understood salaries to be within the scope of 'expenses.'"  But the dissent relies less on this citation and more on the "plain meaning" of the term, citing Taniguchi v. Kan Pac. Saipan, Ltd., 566 U.S. 560, 566 (2012), for the rubric that plain meaning should be used when Congress has not defined a term with particularity.  Again harkening back to the 1830's, the dissent quotes Webster's original American Dictionary of the English Language as including "employment and compensation" to fall with the scope of "expense" and states that the dictionary definitions cited by the majority actually support its definition of "expenses" to include personnel expenditures and out-of-pocket attorneys' fees.  In addition, the dissent cites Taniguchi (albeit not a Section 145 case or even a patent case) for including attorneys' fees as "expenses."  And the dissent criticizes the majority's reliance on other statutes on the grounds that these statutes were enacted after (and in most cases significantly after) the 1836 Patent Act and the Supreme Court's practice of using contemporaneous statutes in these instances, citing W. Va. Univ. Hosps., Inc. v. Casey, 499 U.S. 83, 88 (1991).

    Next, the dissent distinguishes the majority's argument that other sections of the Patent Act (specifically, § 285) expressly recite attorneys' fees as meaning that failure to do so in § 145 is meaningful for statutory construction here.  The dissent notes its opinion that "Congress intended a broader compensation scheme under § 145 than under § 285" by comparing "[a]ll the expenses of the proceedings" with "reasonable attorneys' fees," saying that "Congress can certainly employ a broad word over other narrower alternatives if it so chooses."  Additionally, the "overhead" aspect of agency attorneys' compensation from which the fees at issue here were calculated is persuasive to the dissenting judges that such fees should be considered expenses.  The difference in the "setting" of the two sections (district court litigation versus agency proceedings) are significant to the dissent because "§ 145 proceedings are, 'in fact and necessarily, a part of the application for the patent'" for the dissenters, citing Gandy v. Marble, 122 U.S. 432, 439 (1887).  In this reading of the statute, expenses under §145 "are a direct counterpart to the application fees that are designed to reimburse the PTO's examination expense[s]," for which there is little argument that they are the responsibility of an applicant.

    Once having established that for Chief Judge Prost and her brethren the term "expense" should include agency attorneys' fees, the dissent then considers the use of "all" as emphasizing that the term should be construed broadly (see similar arguments by Chief Justice Burger in Diamond v. Chakrabarty and Justice Scalia in Merck v. Integra).  In Chief Judge Prost's view, the majority's construction would "leave[] little work for 'all' to do" because "simply saying 'the expenses' would seem to do just as well."  According to Chief Judge Prost, "Congress used the word 'all' to broadly and comprehensively capture anything fairly regarded as an 'expense,' resolving any lingering doubt in favor of inclusion [of the PTO's attorneys; fees as part of the Office's "expenses"]."

    Finally, the dissenting opinion sites the legislative history (from the 1836, 1839, and 1870 Patent Acts), justifying this analysis by Supreme Court practice in assessing fee shifting in the context of the American Rule; see Ruckelshaus v. Sierra Club, 463 U.S. 680, 686–91 (1983), and Summit Valley Indus., Inc. v. Local 112, United Bhd. of Carpenters & Joiners of Am., 456 U.S. 717, 723–24 (1982).  According to the dissent, review of this record shows that "Congress intended all of the expenses associated with § 145 proceedings to be borne by the applicants who elect them—not by taxpayers or other PTO users whose fees fund the agency's operations.  Section 145 proceedings are an optional extension of the application process."  Further:

    An applicant's choice to proceed under § 145 diverts the agency's resources from the PTO's principal mission of examining patent and trademark applications at the agency.  The purpose of § 145's expense-reimbursement provision is to ensure that these expenses fall on the applicants who elect the more expensive district court proceedings over the standard appeal route [emphasis added].

    Regarding the role of the American Rule in the dissenting opinion, Chief Judge Prost reviewed the Fourth Circuit's Shammas decision contrary to the majority here.  The American Rule does not apply, either under Shammas or, in the dissent's view, here because expenses are assessed against an applicant regardless of whether the application prevails or does not.  And the dissent states that these judges disagree with the majority even if the American Rule was held to apply.

    The dissent concludes with a discussion of various policy considerations, including applicant "choice" between appeal to the Federal Circuit and district court (neglecting to consider the procedural necessities that may influence an applicant's choice); that any "special solicitude" extended by the majority over the financial burden on "small businesses and individual inventors" is "entirely speculative," citing Baker Botts L.L.P. v. ASARCO LLC, 135 S. Ct. 2158, 2169 (2015) (quoting Lamie v. United States Tr., 540 U.S. 526, 538 (2004)), for the principle that "'[the Supreme Court's] unwillingness to soften the import of Congress'[s] chosen words even if [the Court] believe[s] the words lead to a harsh outcome is longstanding.'"  Concern over such costs is also lessened by the cost of experts and other expenses not at issue here that can themselves be considerable, according to the dissent.  Acknowledging these costs implicates who should pay them, which is an easy choice for the dissent:

    [W]hile it may be true that the PTO's personnel expenses in some cases might amount to a significant sum for applicants who choose to proceed down the optional § 145 route, those expenses have to be paid by someone.  As the PTO observes, at Congress's direction, the PTO now must operate entirely as a user-funded agency.  All applicants pay a number of fees throughout the patent-examination process to cover the PTO's expenses of operation.  Thus, in asking this court to exclude personnel expenses from "[a]ll the expenses of the proceedings," NantKwest asks this court to require other PTO applicants to pay the PTO's personnel expenses incurred in response to its §145 complaint, rather than NantKwest itself.  This contravenes Congress's intent [references to PTO brief omitted].

    That the Office has never demanded applicants to pay attorneys' fees is another aspect of this case having no weight to the dissenting judges.  "Given how dramatically the patent and litigation landscapes have changed since the provision was first enacted, it is hardly surprising that the PTO would have felt compelled in recent years to change its strategy," based in part on applicants purportedly using §145 proceedings more frequently and their costs becoming greater in recent years.

    These questions of policy, while outside the scope of the question before the Court or the Court's purview in making these judgments, are in the dissent's view relevant as evincing Congress's choices in enacting § 145 to require an applicant to pay "all expenses of the proceedings" including the PTO's attorneys' fees.

    NantKwest, Inc. v. Iancu (Fed. Cir. 2018) (en banc)
    Panel: Chief Judge Prost and Circuit Judges Newman, Lourie, Dyk, Moore, O'Malley, Reyna, Wallach, Taranto, Hughes, and Stoll; Circuit Judge Chen did not participate.
    Opinion by Circuit Judge Stoll, joined by Circuit Judges Newman, Lourie, Moore, O'Malley, Wallach, and Taranto; dissenting opinion by Chief Judge Prost, joined by Circuit Judges Dyk, Reyna, and Hughes

  • CalendarJuly 31, 2018 – "Structuring Freedom to Operate Opinions: Reducing Risk of Patent Infringement — Combating Troubling FTO Results, Overcoming Potential Roadblocks, Addressing Impact of Post-Grant Process on FTO Opinions" (Strafford) – 1:00 to 2:30 pm (EDT)

    August 9, 2018 – "Hatch-Waxman Litigation and 30-Month Stays: Multiple Stays, Late-Listed Patents, and More" (Strafford) – 1:00 to 2:30 pm (EDT)

    August 16, 2018 – "Patent Drafting for Machine Learning: Structural Claim Limitations, Avoiding 101 or 112 Rejections" (Strafford) – 1:00 to 2:30 pm (EDT)

    August 16-17, 2018 – "Advanced Patent Prosecution Workshop 2018: Claim Drafting & Amendment Writing" (Practising Law Institute) – San Francisco, CA

    August 21, 2018 – "Navigating the Patent Prosecution Highway and Other Accelerated Filing Options — Evaluating the Different Options, Weighing the Benefits and Risks, Obtaining Patent Protection" (Strafford) – 1:00 to 2:30 pm (EDT)

    September 21, 2018 – "USPTO Post-Grant Patent Trials 2018: Change & Recalibration" (Practising Law Institute) – New York & Groupcasts in Philadelphia, Indianapolis, New Brunswick, NJ, Pittsburgh, and Mechanicsburg, PA

    September 27-28, 2018 – "Advanced Patent Prosecution Workshop 2018: Claim Drafting & Amendment Writing" (Practising Law Institute) – Chicago, IL

  • Strafford #1Strafford will be offering a webinar entitled "Navigating the Patent Prosecution Highway and Other Accelerated Filing Options — Evaluating the Different Options, Weighing the Benefits and Risks, Obtaining Patent Protection" on August 21, 2018 from 1:00 to 2:30 pm (EDT).  Ralph G. Fischer and Duane A. Stewart, III of Buchanan Ingersoll & Rooney will provide guidance to patent counsel on the use of the Patent Prosecution Highway (PPH) and other ways to fast track examination, examine the pros and cons of options and discuss factors to consider when determining whether to pursue accelerated prosecution and which avenue to take, and offer best practices for avoiding common mistakes and obtaining patent protection.  The webinar will review the following issues:

    • What options are available to accelerate a patent prosecution, and what are the pros and cons of each?
    • What factors should patent counsel consider when determining whether seeking accelerated patent protection is the best avenue for prosecution?
    • What are the key considerations for patent counsel drafting applications when accelerated patent protection is anticipated?

    The registration fee for the webcast is $297.  Those interested in registering for the webinar, can do so here.

  • Strafford #1Strafford will be offering a webinar entitled "Patent Drafting for Machine Learning: Structural Claim Limitations, Avoiding 101 or 112 Rejections" on August 16, 2018 from 1:00 to 2:30 pm (EDT).  Gregory Rabin of Schwegman Lundberg & Woessner and Michael D. Stein of Baker & Hostetler will guide patent practitioners in overcoming the challenges when seeking patent protection for machine learning inventions, and also discuss what can be done to anticipate and minimize the risks of § 101 or § 112 rejections.  The webinar will review the following issues:

    • What are the hurdles for patent counsel to demonstrate inventorship?
    • How can patent counsel meet the requirements under §101 and §112 in machine learning patent applications?
    • What steps should patent counsel take to minimize the likelihood of §101 or §112 rejections?

    The registration fee for the webcast is $297.  Those interested in registering for the webinar, can do so here.

  • By Donald Zuhn

    USPTO SealIn a decision issued in May, the Patent Trial and Appeal Board of the U.S. Patent and Trademark Office reversed the final rejection of claims 35-48 in U.S. Application No. 13/512,585.  The claims at issue had been rejected by the Examiner under 35 U.S.C. § 103(a) as being unpatentable over U.S. Patent No. 7,056,690 ("Laskey") in view of Pajor et al., International Society for Analytical, Cytometry Part A. (2008) ("Pajor"), and Stoeber et al., J. Nat. Cancer Inst. 94(14): 1071-79 (2002) ("Stoeber"), and under 35 U.S.C. § 101 as being directed to a judicial exception without significantly more.

    The '585 application relates to a screening method for bladder cancer.  Representative claim 35 recites:

    35.  A method of diagnosing a subject with bladder cancer or at risk of developing bladder cancer comprising:
        a) providing a urine sample isolated from said subject;
        b) isolating cells from said sample and dispersing them on a slide, wherein said slide contains at least 5000 total cells;
        c) contacting said cells with a labelled specific binding member capable of binding to a minichromosome maintenance 2 (MCM2) polypeptide to stain cells with that express MCM2; and
        d) counting said stained cells to provide a cell count;
        wherein if said cell count is at least 50 cells of said 5000 total cells said subject has bladder cancer or is at risk of developing bladder cancer.

    In reversing the Examiner's § 103 rejection, the Board began by citing CFMT, Inc. v. Yieldup Intern. Corp., 349 F.3d 1333, 1342 (Fed. Cir. 2003), for the proposition that "[o]bviousness requires a suggestion of all limitations in a claim."  The Board noted that the Examiner had determined that Laskey teaches all of the claimed elements except for dispersing 5000 total cells on a slide and then counting MCM2 positive cells, and that Pajor and Stoeber teach those elements.  In particular, the Examiner had determined that:

    One of ordinary skill in the art at the time the invention was made would have been motivated to . . . count dispersed cells expressing MCM2 by performing the method of Pajor et al using the labeled anti-MCM2 antibodies of Laskey et al wherein the presence of (including 50 or more) MCM2-expressing cells is indicative of bladder cancer.

    The Board determined, however, that the Examiner failed to establish that either Stoeber or Pajor teaches the claimed step of counting cells.  With respect to Stoeber, the Board noted that this reference teaches the calculation of the fluorescence of batch cell lysate samples labeled with Mcm5 antibody by Dissociation-Enhanced Lanthanide Fluorometric Immunoassay (DELFIA).  The Board concluded that "[t]he Examiner points to no evidence or disclosure in Stoeber that individual cells were counted, and makes no supported finding that one of ordinary skill in the art would understand a correlation between a batch fluorescence value of cells and individual cell counts."

    As for Pajor, the Board noted that this reference discloses the scanning of CK-7 and hematoxylin stained cell samples on slides from voided urine by examining predefined areas of the slides using immunostain microscopy.  The Board concluded that "[t]he Examiner points to no evidence or disclosure in Pajor that individual cells were counted, and makes no supported finding that one of ordinary skill in the art would have understood there to be a correlation between a fluorescent intensity of cells obtaining by immunostain microscopy and individual cell counts."

    The Board therefore reversed the Examiner's obviousness rejection, finding that "the Examiner has not provided evidence of each and every method step claimed, in particular the claimed cell counting step."

    In reversing the Examiner's § 101 rejection, the Board noted that the Examiner had determined that the judicial exception to which the claims were directed was the natural phenomenon of "elevated numbers of MCM2 expressing cells in urine [that] are indicative of bladder cancer or risk of developing bladder cancer."  The Examiner had also determined that "in the instant case, the claims only recite well-understood, routine and conventional limitations in addition to the judicial exception(s)."  In particular, the Examiner had determined that:

    [D]etection methods encompassed by the instant claims are well[-]known, routine, and conventional.  The claims do not include additional elements that are sufficient to amount to significantly more than the judicial exception because the additional elements (common methods of detecting expression and common therapeutic methods) are routinely performed in the art to obtain data regarding expression and treat subjects.

    Appellants, however, argued that the Examiner's assertion that the additional claim elements consisted of well-understood, routine, and conventional methods of detecting a known bladder cancer urine biomarker (MCM2 of Laskey) by modifying the generic method of Pajor was "conclusory and fails to consider the claims as a whole."  Appellants also argued that "the combination of Laskey and Pajor does not even provide all limitations of the claim and are conflicting technologies, not providing a routine path to practice the claims."

    The Board concluded that the Examiner failed to provide evidence to support a prima facie case of patent ineligible subject matter, citing Berkheimer v. HP Inc., 881 F.3d 1360, 1369 (Fed. Cir. 2018), for the proposition that "[w]hether something is well-understood, routine, and conventional to a skilled artisan at the time of the patent is a factual determination."  In particular, the Board noted that "the Examiner did not establish with factual evidence, that the cell counting step, as claimed, is conventional or known in the art."  The Board therefore reversed the Examiner's rejection of the claims at issue under § 101.

    Ex parte Galloway (PTAB 2018)
    Panel: Administrative Patent Judges Adams, Mills, and Jenks
    Decision on Appeal by Administrative Patent Judge Mills

    Hat tip to Warren Woessner of Schwegman Lundberg & Woessner and Patents4Life for bringing the above decision to our attention.

  • By Michael Borella

    USPTO SealEarlier this month, the Patent Trial and Appeal Board (PTAB) of the U.S. Patent and Trademark Office (USPTO) changed a number of decisions to "informative" status.  An informative decision reflects "the Board's general consensus on recurring issues and guidance to examiners, appellants, patent owners, or petitioners in areas where parties routinely misapply the law" (see PTAB's Designations for Opinions)

    One of these opinions is Ex Parte Jung, initially published in March of last year.  In it, the PTAB clarifies how a certain commonly-used claiming technique could be construed as either in the conjunctive or disjunctive depending on the disclosure of the specification.  While this interpretation is not new and dates back to a 2004 Federal Circuit opinion, many practitioners still use similar language in claims with the intent for these claims to be interpreted in the disjunctive only.  Therefore, it is worth revisiting this case.

    The relevant sections of a representative claim recite (formatted for clarity and with emphasis added):

        receiving, by the control point, one or more scene objects comprising the scene to be played back from the media server in response to the request, each scene object including metadata representing at least one of
            
    a precedence relation indicating the scene object's location in a sequence of scene objects and
            a connection relation indicating one or more scene objects capable of replacing the scene object, the connection relation including at least one of
                
    a connection branch and
                a contents connection list having a first group identification…

    This claim was rejected as obvious over a combination of two references.  The Applicant took the position that the first reference failed to teach what the Examiner relied upon it for, a "connection relation including at least one of a connection branch and a contents connection list."  The Applicant further took the position that the second reference also failed to teach that feature, as well as "at least one of a precedence relation indicating the scene object's location in a sequence of scene objects and a connection relation indicating one or more scene objects."

    Getting straight to the point, the PTAB stated that the plain meaning of claim language in the form of "at least one of A and B" is conjunctive and such language should be interpreted as "at least one of A and at least one of B."  This interpretation was set forth by the Federal Circuit in SuperGuide Corp. v. DirecTV Enters., Inc., and is based on the principle (from Strunk and White's Elements of Style) that "an article of a preposition applying to all the members of the series must either be used only before the first term or else be repeated before each term."

    Such a construction, however, does not apply when "the patent's claims, specification, or prosecution history necessitate a broader meaning."  Thus, in some situations, "at least one of A and B" is properly construed in the disjunctive as "at least one of A or B."  For example, if the specification suggests that only one of A or B is to be selected, then the disjunctive interpretation should be applied.

    In the case at hand, the Examiner interpreted the first instance of "at least one" in the claim as referring to either a precedence relation or a connection relation.  But the Examiner did not support this interpretation with any reasoning.  Thus, the PTAB instead applied plain and ordinary meaning per SuperGuide to find that this term should have been interpreted as conjunctive.  The PTAB wrote: "like any claim construction straying from the ordinary meaning, the Examiner should set forth the reasoning for such an interpretation, including citations and explanations of relevant portions of the claims, specification, or prosecution history."  Furthermore, the PTAB's analysis of the specification resulted in a conclusion that while both a conjunctive and disjunctive interpretation was supported therein, there was no "clear definition or disavowal which would compel a disjunctive construction."

    Regarding the second instance of "at least one" in the claim, the PTAB found support for a disjunctive interpretation.  But, it stated that "neither the claims nor the remainder of the Specification ever suggest that a connection branch and a contents connection list must be mutually exclusive . . . [t]hus, nothing compels interpreting 'and' to mean 'or' contrary to its ordinary meaning."

    Therefore, both instances of "at least one" were properly construed as conjunctive.  As a result, the PTAB reversed the Examiner's obviousness rejections, as the PTAB's claim construction was sufficiently narrower than that of the Examiner to avoid reading on the cited references.  The irony here, however, is that the narrower construction of "at least one of a connection branch and a contents connection list" was not adequately supported by the specification.  Consequently, the claims were rejected under 35 U.S.C. § 112, first paragraph for lack of written description.

    The practice tip here is that a claim term in the form of "at least one of A and B" will be interpreted in the conjunctive unless the Applicant clearly requires a disjunctive interpretation.  Nonetheless, numerous practitioners are unaware of SuperGuide and still expect such a term to mean "A or B."  A safe bet for those who wish to claim in the conjunctive or disjunctive is to use "A and B" or "A or B", respectively.  With appropriate support in the specification, of course.

    Ex parte Jung (PTAB 2018)
    Panel: Administrative Patent Judges MacDonald, Horner, and Engle
    Decision on Appeal by Administrative Patent Judge MacDonald

  • By Michael Borella

    Federal Circuit SealInterval Licensing brought an action against AOL and several other defendants in the Western District of Washington, alleging infringement of U.S. Patent No. 6,034,652.  In a previous ruling, all asserted claims of this patent were invalidated as being indefinite.  At issue in this decision are claims 15-18, which were subsequently ruled invalid for failing to recite patent-eligibile subject matter under 35 U.S.C. § 101.

    As an example, claim 18 recites:

    A computer readable medium, for use by a content display system, encoded with one or more computer programs for enabling acquisition of a set of content data and display of an image or images generated from the set of content data on a display device during operation of an attention manager, comprising:
        acquisition instructions for enabling acquisition of a set of content data from a specified information source;
        user interface installation instructions for enabling provision of a user interface that allows a person to request the set of content data from the specified information source;
        content data scheduling instructions for providing temporal constraints on the display of the image or images generated from the set of content data;
        display instructions for enabling display of the image or images generated from the set of content data;
        content data update instructions for enabling acquisition of an updated set of content data from an information source that corresponds to a previously acquired set of content data;
        operating instructions for beginning, managing and terminating the display on the display device of an image generated from a set of content data;
        content display system scheduling instructions for scheduling the display of the image or images on the display device;
        installation instructions for installing the operating instructions and content display system scheduling instructions on the content display system; and
        audit instructions for monitoring usage of the content display system to selectively display an image or images generated from a set of content data.

    According to the Court, the invention involves a software application referred to as an "attention manager."  This application "makes use of 'unused capacity' of a display device, by displaying content in that unused capacity."  Thus it can display "content when the display device is turned on but the user is not actively engaged with the display device" as well as displaying "content in an area of the display screen not used by already-displayed content with which the user is actively engaged."

    In Alice Corp. v. CLS Bank Int'l, the Supreme Court set forth a two-part test to determine whether claims are directed to patent-eligible subject matter under § 101.  One must first decide whether the claim at hand is directed to a judicially-excluded law of nature, a natural phenomenon, or an abstract idea.  If so, then one must further decide whether any element or combination of elements in the claim is sufficient to ensure that the claim amounts to significantly more than the judicial exclusion.  But generic computer implementation of an otherwise abstract process does not qualify as "significantly more," nor will elements that are well-understood, routine, and conventional lift the claim over the § 101 hurdle.

    Applying step one of Alice, the Court quickly concluded that the claimed invention was directed to "providing information to a person without interfering with the person's primary activity."  This, in and of itself, is an abstract idea according to the Court due to it being analogous to news tickers on television programs, for example.  The Court also frowned upon the claim's "broad, result-oriented" structure that "demands the production of a desired result (non-interfering display of two information sets) without any limitation on how to produce that result."

    Regarding step 2, the Court again criticized the claim's lack of detail, stating that it "do[es] not recite any arguably inventive method of how the secondary information is displayed, such as what portion of the screen is utilized or how the primary activity on the screen is monitored."  Interval Licensing argued that the claim "improve[s] computer display devices by combining the acquired information with the user's primary display interaction."  But the Court did not view this ability as an improvement, largely because the claim is broad enough to encompass any mechanism to achieve this goal.  Arguably, this would include prior known mechanisms.

    Consequently, claims 15-18 were ruled invalid as directed to non-eligible subject matter.

    This opinion would just be another ho-hum, run-of-the-mill § 101 decision if not for Judge Plager filing a concurrence-in-part and dissent-in-part.  While not binding law, he has provided the most pointed (and sarcastic) criticism of the Alice test and how § 101 is currently applied that we have yet to hear from a sitting Federal Circuit judge.  Even a casual read of his concurring / dissenting remarks indicate that he has chosen his language carefully.  Thus, we will block quote much of what he wrote.

    He begins with an indication of what is to come:

    Given the current state of the law regarding what inventions are patent eligible, and in light of our governing precedents, I concur in the carefully reasoned opinion by my colleagues in the majority, even though the state of the law is such as to give little confidence that the outcome is necessarily correct.  The law, as I shall explain, renders it near impossible to know with any certainty whether the invention is or is not patent eligible.

    He then indicates that the term "abstract idea" as used by the courts is far removed from its plain meaning:

    An idea itself by definition is "[s]omething, such as a thought or conception, that is the product of mental activity."  The definitions of "abstract" include "[c]onsidered apart from concrete existence," "[d]ifficult to understand; abstruse," and "[n]ot applied or practical; theoretical."  An idea, whether abstract or not, is something that lives in the interstices of someone's brain, a psychophysiological area not fully understood to this day.

    Thus, by the very nature of the term, it is difficult if not impossible to apply the test to claimed inventions, and that focusing on whether a claim is to an outcome or a process to achieve that outcome does little to clarify the situation:

    And ideas can have an infinite range of abstractness, if by that we imply concreteness—for example, compare "I have an idea—let's have hamburgers for dinner," with "I have an idea—I am going to invent how to make time go backwards."  How much of abstractness is a function of concreteness?  How do we pick the line where the articulation and explication of an idea is sufficiently concrete to be 'non-abstract,' but not so much as to be 'generic and conventional'?  Does it help to phrase the notion as the difference between claiming a desired result and claiming how to produce that same result?  Or are we just substituting one set of vague notions for the other, with the same line-drawing problem?

    He backs this up by noting that "a search for a definition of 'abstract ideas' in the cases on § 101 from the Supreme Court, as well as from this court, reveals that there is no single, succinct, usable definition anywhere available."  Further, "[t]he problem with trying to define 'abstract ideas,' and why no court has succeeded in defining it, is that, as applied to as-yet-unknown cases with as-yet-unknown inventions, it cannot be done except through the use of equally abstract terms."

    Judge Plager then fires a shot:  "[t]he 'abstract ideas' idea, when used for denying a claimed invention's patent eligibility either before or after a patent is issued, cannot thus function as a valid rule of law."  Making an analogy to the I-know-it-when-I-see-it notion of obscenity, he writes:  "the 'abstract ideas' idea falls short in the sense of providing a trial judge with confidence that the judgment will be understood by the judges who come after."

    He goes on to question whether step two of Alice, the search for an "inventive concept" in an abstract claim, makes any sense at all:

    A small puzzle—if a court, after reviewing challenged claims in light of their terminology and written description, determines the claims to be 'abstract' in Step 1, how can the same court be expected to determine on a second reading that the same claims have become 'un-abstract' via Step 2?  Could it be that an 'inventive concept' cannot exist until the court reads the patent at least one more time?  Perhaps courts cannot be expected to read the claims carefully enough the first time?

    Judge Plager then makes an analogy between the notion of an inventive concept and similar "inventive requirements" that were eliminated from the § 103 obviousness inquiry by the 1952 Patent Act:

    As a decisional construct for validation of a property right—a patent—the idea of a necessarily underlying 'inventive concept' proved unworkable.  The concept provided no discernable boundaries for decision-making in specific cases, resulting in an incoherent legal rule that led to arbitrary outcomes.  Judge Rich, who devoted his life to patent law, saw this clearly, and gave the Congress a workable alternative—nonobvious subject matter—which they adopted.

    Finally, Judge Plager focuses on recent criticism of Alice from his colleagues, Judges Linn and Lourie, as well as academics, commentators, and the former head of the USPTO.  He also points to the bases of this criticism:

    There is little consensus among trial judges (or appellate judges for that matter) regarding whether a particular case will prove to have a patent with claims directed to an abstract idea, and if so whether there is an 'inventive concept' in the patent to save it.  In such an environment, from the viewpoint of counsel for the defense, there is little to be lost in trying the § 101 defense.  We are left with a process for finding abstract ideas that involves two redundant steps and culminates with a search for a  concept—inventiveness—that some 65 years or so ago was determined by Congress to be too elusive to be fruitful.  Is it any wonder that the results of this process are less than satisfactory?

    Turning to those who view modern, information-age inventions with disfavor, he adds:

    With the rise of software and business method patents, the 'abstract idea' became a weapon of choice for summary execution of what many decried as 'bad' patents.  The problem is that it does not distinguish good from ill in any coherent sense, and thus does not serve well either patent law or the public.

    Judge Plager then encourages district courts to defer § 101 determinations until after challenges under §§ 102, 103, and 112 have been decided, and suggests that many of the so-called "bad" patents killed off under § 101 would fail to meet these other statutory requirements.  Thus, in his view, there is no need to address § 101 on the pleadings for example.

    Judge Plager finishes with another strong statement:

    This emperor clearly has no clothes; we need not wait for our children to tell us this.  The legitimate expectations of the innovation community, as well as basic notions of fairness and due process, compel us to address this § 101 conundrum.

    There is little that Judge Plager writes in this concurrence / dissent that has not already been said many times by many individuals.  But his position as an active appellate jurist and the power of his choice of words lend additional weight to the growing sense of institutional disapproval over current patent-eligibility practice.  There still might not be enough momentum for the Supreme Court or Congress to rectify the situation, but a strong voice that cannot be ignored has joined the fray.

    Interval Licensing LLC v. AOL, Inc. (Fed. Cir. 2018)
    Panel:  Circuit Judges Taranto, Plager, and Chen
    Opinion by Circuit Judge Chen; opinion concurring-in-part and dissenting-in-part by Circuit Judge Plager